HighMark Wealth Management’s Centessa Pharmaceuticals CNTA Stock Holding History

HighMark Wealth Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-236,785	Closed	-$9.41M	–	572
2026 Q1	$9.41M	Hold	236,785	–	–	3.83%	7
2025 Q4	$5.92M	Sell	236,785 -500	-0.2%	-$12.7K	2.41%	10
2025 Q3	$5.75M	Hold	237,285	–	–	2.53%	9
2025 Q2	$3.12M	Buy	237,285 +1,500	+0.6%	+$19K	1.52%	13
2025 Q1	$3.39M	Buy	235,785 +69,650	+42%	+$1.14M	2%	9
2024 Q4	$2.78M	Sell	166,135 -1,000	-0.6%	-$16.6K	1.6%	10
2024 Q3	$2.67M	Buy	167,135 +74,135	+80%	+$908K	1.46%	11
2024 Q2	$840K	Buy	+93,000	New	+$882K	0.51%	27

HighMark Wealth Management's CNTA Position: Q2 2026 in Review

HighMark Wealth Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 236,785 shares — an estimated $9.41M sold.

HighMark Wealth Management first reported a position in CNTA in Q2 2024 and held it in 8 quarters. The position peaked at $9.41M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

HighMark Wealth Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HighMark Wealth Management sold 236,785 Centessa Pharmaceuticals shares in Q2 2026, an estimated $9.41M.
HighMark Wealth Management first reported a position in Centessa Pharmaceuticals in Q2 2024 and held it in 8 quarters.
HighMark Wealth Management's Centessa Pharmaceuticals position peaked at $9.41M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.